Hôpital Tenon

Running trials

• Not yet recruiting

  Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer

  NCT07857486· Phase 2· Institut Paoli-Calmettes· Source

• Not yet recruiting

  Assessment of Dietary Balance in Home-Dwelling Patients With Stage 4 and 5 Chronic Kidney Disease Using URIKI (IKI), a Connected Urine Test Strip and In Vitro Diagnostic Medical Device

  NCT07746037· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

  NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer

  NCT07828938· Fondation Hôpital Saint-Joseph· Source

• Not yet recruiting

  SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

  NCT07241273· UNICANCER· Source

• Not yet recruiting

  Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

  NCT07357948· Institut Curie· Source

• Recruiting

  Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease

  NCT07274254· Phase 3· Nantes University Hospital· Source

• Recruiting

  Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.

  2025-521437-88-00· Phase 2· Groupe Oncologie Radiotherapie Tete Cou· Source

• Recruiting

  Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease

  2024-518437-28-00· Phase 3· Centre Hospitalier Universitaire De Nantes· Source

• Not yet recruiting

  Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

  2025-523610-83-00· Phase 4· Institut Gustave Roussy· Source

• Recruiting

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source

• Recruiting

  Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations

  NCT07739121· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

  NCT07299071· University Hospital, Bordeaux· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

  NCT07043543· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Not yet recruiting

  IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

  2025-521908-22-00· Phase 2/3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  Early detection of triple negative breast cancer relapse (CUPCAKE)

  2022-501562-22-01· Phase 2· Institut Curie· Source

• Recruiting

  Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

  NCT06225505· Institut Curie· Source

• Recruiting

  Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

  NCT06908993· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

  NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

  NCT06790706· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

  NCT07243132· GFPC Investigation· Source

• Recruiting

  Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

  NCT06350630· Phase 2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Recruiting

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· Phase 2· Groupe Francais De Pneumo-Cancerologie· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· Phase 2· Swedish Orphan Biovitrum· Source

• Recruiting

  Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

  NCT06934057· Phase 4· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV viruses

  2023-508634-34-00· Phase 2· Inserm· Source

• Recruiting

  MODULO

  NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source

• Recruiting

  Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

  NCT06522256· ANRS, Emerging Infectious Diseases· Source

• Recruiting

  LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.

  2022-501315-13-00· Phase 3· Centre Leon Berard· Source

• Recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  NCT06767514· Phase 3· Summit Therapeutics· Source

• Recruiting

  Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

  NCT06706401· Phase 3· Centre Leon Berard· Source

• Recruiting

  PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial

  2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

  2023-503675-24-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

  NCT06646471· Phase 4· GFPC Investigation· Source

• Recruiting

  Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis

  NCT06368804· Phase 2· Centre Hospitalier Intercommunal Creteil· Source

• Recruiting

  A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

  NCT06362252· Phase 1/2· Daiichi Sankyo· Source

• Active, not recruiting

  PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

  NCT06172127· Phase 2· MedSIR· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

  NCT06393816· Phase 2· Centre Leon Berard· Source

• Recruiting

  FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.

  2023-506590-35-00· Phase 2· Centre Leon Berard· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Daiichi Sankyo· Source

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source

Showing 50 of 118.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer24 recruiting
• Triple-negative breast cancer7 recruiting
• Head and neck cancer6 recruiting
• Prostate cancer6 recruiting
• Kidney cancer5 recruiting
• Bladder cancer3 recruiting
• Colorectal cancer3 recruiting
• HIV3 recruiting
• Ovarian cancer3 recruiting
• Childhood cancers2 recruiting
• Chronic kidney disease2 recruiting
• High blood pressure2 recruiting
• Lupus (SLE)2 recruiting
• Metastatic breast cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Sarcoma2 recruiting
• Sickle cell disease2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bronchiectasis1 recruiting
• Cystic fibrosis1 recruiting
• Endometriosis1 recruiting
• Hepatitis B1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Multiple sclerosis1 recruiting
• Rheumatoid arthritis1 recruiting
• Tuberculosis1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· Phase 2· Organon LLC· Source

• Completed

  Molecular Diagnosis of Lung Cancer Via Bronchoscopy: The Significance of Bronchial Liquid Biopsy (ctDNA and ctRNA)

  NCT06228508· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.

  2022-502584-38-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER)

  2022-502360-21-00· Phase 2· Institut Curie· Source

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis

  2022-502045-10-00· Phase 2· Bioprojet Pharma· Source

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Janssen-Cilag Ltd.· Source

• Terminated

  CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

  NCT05546606· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Nantes University Hospital· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Completed

  Use of MULTIplex PCR, procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation: a trial controlled, randomized, open, in parallel groups, multicenter

  2024-511896-13-00· Phase 4· Assistance Publique Hopitaux De Paris· Source

• Active, not recruiting

  Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

  NCT05609578· Phase 2· Mirati Therapeutics Inc.· Source

• Completed

  Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)

  NCT05489120· Dr. Schär AG / SPA· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Organon and Co· Source

• Completed

  Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

  NCT06525675· MedSIR· Source

• Completed

  Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

  NCT05030155· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

  NCT05267470· Phase 1· Amgen· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Active, not recruiting

  Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

  NCT05486182· Phase 4· GE Healthcare· Source

• Completed

  Interrupters of VAscular daMAge in Malignant Hypertension

  NCT04991077· Centre Hospitalier de PAU· Source

• Completed

  Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour

  NCT04760496· Phase 4· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  NCT04564339· Phase 2· Alexion Pharmaceuticals Inc.· Source

• Terminated

  Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

  NCT04698915· Phase 2· Galera Therapeutics, Inc.· Source

• Completed

  Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)

  NCT04597424· Phase 3· ANRS, Emerging Infectious Diseases· Source

• Completed

  Immunotherapy in Patient With Poor General Condition

  NCT04108026· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Hoffmann-La Roche· Source

• Completed

  Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

  NCT04111705· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Completed

  A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

  2023-505035-12-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Completed

  Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

  NCT04223791· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  NOLA (NeuWave Observational Liver Ablation) Registry

  NCT04107766· Ethicon, Inc.· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Takeda· Source

• Completed

  Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

  NCT03838263· Phase 2· UNICANCER· Source

• Completed

  Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck

  2024-513977-31-00· Phase 2· Groupe Oncologie Radiotherapie Tete Cou· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source

• Completed

  Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer

  2024-515533-15-00· Phase 2· Institut Gustave Roussy· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Completed

  Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

  NCT03469960· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Oral Anticoagulation in Haemodialysis Patients

  NCT02886962· Phase 4· University Hospital, Strasbourg, France· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

  NCT02784171· Phase 2/3· Canadian Cancer Trials Group· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source

• Terminated

  Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone

  NCT02806258· Phase 1/2· University Hospital, Grenoble· Source

• Active, not recruiting

  AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

  NCT02511106· Phase 3· AstraZeneca· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Endometriosis15 works · 3 trials
• Sickle cell disease9 works · 2 trials
• IgA nephropathy5 works · 4 trials